

Aneliya Ilieva Parvanova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9844593/publications.pdf>

Version: 2024-02-01

27
papers

2,245
citations

471509

17
h-index

580821

25
g-index

27
all docs

27
docs citations

27
times ranked

2864
citing authors

#	ARTICLE	IF	CITATIONS
1	Preventing Microalbuminuria in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2004, 351, 1941-1951.	27.0	952
2	Glomerular Hyperfiltration and Renal Disease Progression in Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 2061-2068.	8.6	259
3	Insulin Resistance and Microalbuminuria. <i>Diabetes</i> , 2006, 55, 1456-1462.	0.6	169
4	Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 301-312.	11.4	166
5	The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. <i>Kidney International</i> , 2013, 84, 164-173.	5.2	131
6	Effects of Manidipine and Delapril in Hypertensive Patients With Type 2 Diabetes Mellitus. <i>Hypertension</i> , 2011, 58, 776-783.	2.7	86
7	Measurable Urinary Albumin Predicts Cardiovascular Risk among Normoalbuminuric Patients with Type 2 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1717-1724.	6.1	80
8	Renal and Systemic Effects of Calorie Restriction in Patients With Type 2 Diabetes With Abdominal Obesity: A Randomized Controlled Trial. <i>Diabetes</i> , 2017, 66, 75-86.	0.6	66
9	Insulin Resistance and Proliferative Retinopathy: A Cross-Sectional, Case-Control Study in 115 Patients with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 4371-4376.	3.6	42
10	Effect of the Urotensin Receptor Antagonist Palosuran in Hypertensive Patients With Type 2 Diabetic Nephropathy. <i>Hypertension</i> , 2010, 55, 1206-1209.	2.7	39
11	Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2013, 1, 19-27.	11.4	37
12	Preventing Left Ventricular Hypertrophy by ACE Inhibition in Hypertensive Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2008, 31, 1629-1634.	8.6	33
13	Effects of Combined Ezetimibe and Simvastatin Therapy as Compared With Simvastatin Alone in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2010, 33, 1954-1956.	8.6	29
14	ADAMTS13 Predicts Renal and Cardiovascular Events in Type 2 Diabetic Patients and Response to Therapy. <i>Diabetes</i> , 2013, 62, 3599-3609.	0.6	25
15	Blood Pressure and Metabolic Effects of Acetyl-L-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial. <i>Journal of the Endocrine Society</i> , 2018, 2, 420-436.	0.2	25
16	Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 27-40.	11.4	24
17	Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes. <i>Diabetic Medicine</i> , 2018, 35, 1375-1382.	2.3	24
18	Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1177-1190.	4.4	14

#	ARTICLE	IF	CITATIONS
19	Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes. <i>Frontiers in Genetics</i> , 2019, 10, 681.	2.3	11
20	Long-term kidney and systemic effects of calorie restriction in overweight or obese type 2 diabetic patients (C.Re.S.O. 2 randomized controlled trial). <i>Diabetes Research and Clinical Practice</i> , 2022, 185, 109804.	2.8	10
21	Hyperhomocysteinemia and Increased Risk of Retinopathy: A cross-sectional, case-control study in patients with type 2 diabetes. <i>Diabetes Care</i> , 2002, 25, 2361-2361.	8.6	8
22	Preventing microalbuminuria with benazepril, valsartan, and benazeprilâ€“valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study. <i>PLoS Medicine</i> , 2021, 18, e1003691.	8.4	7
23	Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1931-1942.	1.8	4
24	SaO006INCREASED PRE-GLOMERULAR RESISTANCE AND KIDNEY HYPOPERFUSION MAY SUSTAIN ACCELERATED GFR DECLINE IN HYPERTENSIVE, TYPE 2 DIABETICS WITH NORMAL AND HIGH NORMAL ALBUMINURIA. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i317-i317.	0.7	2
25	Glomerular resistances predict long-term GFR decline in type 2 diabetic patients without overt nephropathy: a longitudinal subgroup analysis of the DEMAND trial. <i>Acta Diabetologica</i> , 2022, 59, 309-317.	2.5	2
26	FC003: Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Hyperfiltration In Subjects with Prediabetes and Abdominal Obesity Without Evidence of Chronic Kidney Disease. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
27	MO446: The Prevalence of Mafld in Subjects With Normoglycaemia, Prediabetes and Type 2 Diabetes Without Evidence of Chronic Kidney Disease and its Association With Glomerular Hyperfiltration. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0